Express Mail Label No.: EV804431626US

Date of Deposit: August 16, 2006 Attorney Docket No.: VPI/99-109 DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/779,532

Confirmation No.:

5593

Filing Date:

February 13, 2004

Examiner:

Deepak R. Rao

Group Art Unit:

1624

Applicants:

Jeremy Green et al.

For:

AUG 1 6 2006

INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND

OTHER PROTEIN KINASES

August 16, 2006 Cambridge, Massachusetts

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT REGARDING SEQUENCE LISTING

Sir:

Pursuant to 37 C.F.R. §1.821(e), I hereby state that the information recorded in computer readable form (CRF) is identical to the paper copy of the Sequence Listing and that the paper and CRF copies of the Sequence Listing do not include new matter.

Respectfully submitted,

Karen E. Brown, Reg. No. 43,866

Attorney for Applicants

c/o Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, MA 02139-4242

Tel.: (617) 444-6168 Fax.: (617) 444-6483 Customer No. 27916

OIPE		
/ E	Application No.	Applicant(s)
Notice to Complyius 1 6 2006	10/779,532	GREEN, JEREMY
tvotice to complyion 16 2000	Examiner	Art Unit 1624
	RAO, DEEPAK	
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES		
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).		
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):		
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).		
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). The correct SEQ ID NO:2 is present in the paper copy of the of the sequence listing only. Therefore a search of the correct sequence is not possible.		
☐ 7. Other:		
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".		
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.		
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).		
For questions regarding compliance to these requirements, please contact:		
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-42 Patentln Software Program Support Technical Assistance To Purchase Patentln Software	12 or 308-2923 703-287-0200	
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY		